



---

Date: October 27, 2016

To: All Part D Plan Sponsors & Pharmaceutical Manufacturers

From: Amy Larrick Chavez-Valdez  
Director, Medicare Drug Benefit and C&D Data Group

Subject: Comprehensive Addiction and Recovery Act of 2016 (CARA) – Programs to Prevent Prescription Drug Abuse Under Medicare Parts C and D (Sec. 704) Stakeholder Meeting (CMS-4183-N)

The purpose of this memo is to make you aware of the Federal Register announcement for a public meeting to solicit input from stakeholders regarding our implementation of section 704 of the Comprehensive Addiction and Recovery Act of 2016 (CARA) (Pub. L. 114-198), this section includes provisions to permit Part D sponsors to establish drug management programs for at-risk beneficiaries under which Part D sponsors may limit such beneficiaries' access to frequently abused drugs to certain prescribers and pharmacies. The Federal Register notice is located at: [www.federalregister.gov/documents/2016/10/26/2016-25806/medicare-program-listening-session-regarding-the-implementation-of-certain-medicare-part-d](http://www.federalregister.gov/documents/2016/10/26/2016-25806/medicare-program-listening-session-regarding-the-implementation-of-certain-medicare-part-d).

The stakeholder meeting will be held via teleconference on Monday, November 14, 2016 from 1 PM to 4 PM, Eastern Standard Time (EST). Individuals may register online at [www.cms.gov/Outreach-and-Education/training/CTEO/Upcoming\\_Current\\_events.html](http://www.cms.gov/Outreach-and-Education/training/CTEO/Upcoming_Current_events.html). In addition to participating in the stakeholder meeting, written comments or statements on the topics included in the notice may be sent via mail or electronically to:

Centers for Medicare & Medicaid Services  
Attn: Chad Buskirk, Mail Stop C1-24-23  
7500 Security Boulevard  
Baltimore, MD 21244-1850

or by email to [PARTDPOLICY@cms.hhs.gov](mailto:PARTDPOLICY@cms.hhs.gov). In order to be assured consideration, written comments/statements must be received by 5 pm EST, Friday, December 2, 2016.

Questions concerning this memo may be directed to [PartDPolicy@cms.hhs.gov](mailto:PartDPolicy@cms.hhs.gov).